Sino Biopharmaceutical’s Penpulimab Injection Gains US FDA Approval

An update from Sino Biopharmaceutical ( (HK:1177) ) is now available.

Sino Biopharmaceutical Limited announced that its co-developed drug, penpulimab injection, has received approval from the US FDA for marketing. This approval marks a significant milestone as penpulimab is the only novel PD-1 monoclonal antibody with IgG1 subtype and Fc engineering, enhancing efficacy while minimizing adverse reactions. The drug is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and has several approved indications in China. The company plans to further develop penpulimab’s indications and expand into international markets to address urgent clinical needs globally.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and marketing of innovative drugs. The company is involved in the biopharmaceutical industry, with a market focus on creating novel therapies for various cancers and other serious health conditions.

YTD Price Performance: 26.41%

Average Trading Volume: 2,117

Technical Sentiment Signal: Sell

Current Market Cap: $9.23B

Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.